Previous close | 22.13 |
Open | 21.38 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 22.13 - 22.13 |
52-week range | 18.88 - 51.60 |
Volume | |
Avg. volume | 64 |
Market cap | 843.505M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -18.44 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
At this time, I would like to turn the conference over to Julia Neugebauer. My name is Julia Neugebauer, head of investor relations at MorphoSys, and it is my pleasure to welcome you to our half year 2022 financial results conference call. With me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.
DGAP-News: MorphoSys AG / Key word(s): Half Year ResultsMorphoSys AG Reports Second Quarter and First Half 2022 Financial Results 03.08.2022 / 22:01 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 3, 2022MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth Efficacy and safety d
DGAP-News: MorphoSys AG / Key word(s): Half Year ResultsMorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022 28.07.2022 / 22:03 The issuer is solely responsible for the content of this announcement. Conference Call AlertPlanegg/Munich, Germany, July 28, 2022 Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for